Trial · NCT07476625
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Participants Achieving Complete Remission at 6 Months | 6 months | Complete remission is defined as the total absence of febrile episodes (zero attacks) during the treatment period. |
| Secondary | Complete Remission Rate at Multiple Time Points | 3 months | Proportion of participants with zero febrile episodes. |
| Secondary | Complete Remission Rate at Multiple Time Points | 9 months | Proportion of participants with zero febrile episodes. |
| Secondary | Complete Remission Rate at Multiple Time Points | 12 months | Proportion of participants with zero febrile episodes. |
| Secondary | Partial Remission Rate | 3 months | Proportion of participants achieving a reduction in the frequency of febrile episodes compared to baseline. |
| Secondary | Recurrence Rate Post-discontinuation | 6 months post-treatment | Proportion of participants experiencing a relapse of symptoms after stopping the medication. |
| Secondary | Recurrence Rate Post-discontinuation | 12 months post-treatment | Proportion of participants experiencing a relapse of symptoms after stopping the medication. |
| Secondary | Change in Growth Parameters (Z-scores) | 6 months | Changes in Height-for-age Z-score (HAZ) and Weight-for-age Z-score (WAZ). |
| Secondary | Change in Growth Parameters (Z-scores) | 12 months | Changes in Height-for-age Z-score (HAZ) and Weight-for-age Z-score (WAZ). |
| Secondary | Change in Inflammatory Markers | 6 months | Changes in CRP, ESR, SAA, and cytokine levels. |
| Other | Incidence of Adverse Events | 1 month | Percentage of participants experiencing diarrhea, abdominal pain, nausea, liver function abnormality, somnolence, constipation, rash, or peripheral neuropathy (numbness). |
| Other | Incidence of Adverse Events | 6 months | Percentage of participants experiencing diarrhea, abdominal pain, nausea, liver function abnormality, somnolence, constipation, rash, or peripheral neuropathy (numbness). |
| Other | Incidence of Adverse Events | 12 months | Percentage of participants experiencing diarrhea, abdominal pain, nausea, liver function abnormality, somnolence, constipation, rash, or peripheral neuropathy (numbness). |
| Other | Quality of Life (PedsQL-SF15) | 6 months | Change in Pediatric Quality of Life Inventory Short Form 15 scores. |
| Other | Quality of Life (PedsQL-SF15) | 12 months | Change in Pediatric Quality of Life Inventory Short Form 15 scores. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07476625/registered